Deirdre O'Rourke1, Patrick M Chen1, Nicolas Gaspard2,3, Brandon Foreman4, Lauren McClain1, Ioannis Karakis5, Advait Mahulikar6, M Brandon Westover7. 1. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, WACC 735, Boston, MA, 02114, USA. 2. Hôpital Erasme - ULB, Cliniques universitaires de Bruxelles, Brussels, Belgium. 3. Neurology Department, Yale Comprehensive Epilepsy Center, New Haven, CT, USA. 4. Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 5. Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. 6. Department of Neurology, Wayne State University, Detroit, MI, USA. 7. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, WACC 735, Boston, MA, 02114, USA. mwestover@mgh.harvard.edu.
Abstract
BACKGROUND: Generalized triphasic waves (TPWs) occur in both metabolic encephalopathies and non-convulsive status epilepticus (NCSE). Empiric trials of benzodiazepines (BZDs) or non-sedating AED (NSAEDs) are commonly used to differentiate the two, but the utility of such trials is debated. The goal of this study was to assess response rates of such trials and investigate whether metabolic profile differences affect the likelihood of a response. METHODS: Three institutions within the Critical Care EEG Monitoring Research Consortium retrospectively identified patients with unexplained encephalopathy and TPWs who had undergone a trial of BZD and/or NSAEDs to differentiate between ictal and non-ictal patterns. We assessed responder rates and compared metabolic profiles of responders and non-responders. Response was defined as resolution of the EEG pattern and either unequivocal improvement in encephalopathy or appearance of previously absent normal EEG patterns, and further categorized as immediate (within <2 h of trial initiation) or delayed (>2 h from trial initiation). RESULTS: We identified 64 patients with TPWs who had an empiric trial of BZD and/or NSAED. Most patients (71.9%) were admitted with metabolic derangements and/or infection. Positive clinical responses occurred in 10/53 (18.9%) treated with BZDs. Responses to NSAEDs occurred in 19/45 (42.2%), being immediate in 6.7%, delayed but definite in 20.0%, and delayed but equivocal in 15.6%. Overall, 22/64 (34.4%) showed a definite response to either BZDs or NSAEDs, and 7/64 (10.9%) showed a possible response. Metabolic differences of responders versus non-responders were statistically insignificant, except that the 48-h low value of albumin in the BZD responder group was lower than in the non-responder group. CONCLUSIONS: Similar metabolic profiles in patients with encephalopathy and TPWs between responders and non-responders to anticonvulsants suggest that predicting responders a priori is difficult. The high responder rate suggests that empiric trials of anticonvulsants indeed provide useful clinical information. The more than twofold higher response rate to NSAEDs suggests that this strategy may be preferable to BZDs. Further prospective investigation is warranted.
BACKGROUND: Generalized triphasic waves (TPWs) occur in both metabolic encephalopathies and non-convulsive status epilepticus (NCSE). Empiric trials of benzodiazepines (BZDs) or non-sedating AED (NSAEDs) are commonly used to differentiate the two, but the utility of such trials is debated. The goal of this study was to assess response rates of such trials and investigate whether metabolic profile differences affect the likelihood of a response. METHODS: Three institutions within the Critical Care EEG Monitoring Research Consortium retrospectively identified patients with unexplained encephalopathy and TPWs who had undergone a trial of BZD and/or NSAEDs to differentiate between ictal and non-ictal patterns. We assessed responder rates and compared metabolic profiles of responders and non-responders. Response was defined as resolution of the EEG pattern and either unequivocal improvement in encephalopathy or appearance of previously absent normal EEG patterns, and further categorized as immediate (within <2 h of trial initiation) or delayed (>2 h from trial initiation). RESULTS: We identified 64 patients with TPWs who had an empiric trial of BZD and/or NSAED. Most patients (71.9%) were admitted with metabolic derangements and/or infection. Positive clinical responses occurred in 10/53 (18.9%) treated with BZDs. Responses to NSAEDs occurred in 19/45 (42.2%), being immediate in 6.7%, delayed but definite in 20.0%, and delayed but equivocal in 15.6%. Overall, 22/64 (34.4%) showed a definite response to either BZDs or NSAEDs, and 7/64 (10.9%) showed a possible response. Metabolic differences of responders versus non-responders were statistically insignificant, except that the 48-h low value of albumin in the BZD responder group was lower than in the non-responder group. CONCLUSIONS: Similar metabolic profiles in patients with encephalopathy and TPWs between responders and non-responders to anticonvulsants suggest that predicting responders a priori is difficult. The high responder rate suggests that empiric trials of anticonvulsants indeed provide useful clinical information. The more than twofold higher response rate to NSAEDs suggests that this strategy may be preferable to BZDs. Further prospective investigation is warranted.
Entities:
Keywords:
Encephalopathy; Generalized periodic discharges; Non-convulsive status epilepticus; Triphasic waves
Authors: E Wesley Ely; Ayumi Shintani; Brenda Truman; Theodore Speroff; Sharon M Gordon; Frank E Harrell; Sharon K Inouye; Gordon R Bernard; Robert S Dittus Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Ayham Alkhachroum; Brian Appavu; Benjamin Rohaut; Jan Claassen; Satoshi Egawa; Brandon Foreman; Nicolas Gaspard; Emily J Gilmore; Lawrence J Hirsch; Pedro Kurtz; Virginie Lambrecq; Julie Kromm; Paul Vespa; Sahar F Zafar Journal: Intensive Care Med Date: 2022-08-23 Impact factor: 41.787
Authors: Lawrence J Hirsch; Michael W K Fong; Markus Leitinger; Suzette M LaRoche; Sandor Beniczky; Nicholas S Abend; Jong Woo Lee; Courtney J Wusthoff; Cecil D Hahn; M Brandon Westover; Elizabeth E Gerard; Susan T Herman; Hiba Arif Haider; Gamaleldin Osman; Andres Rodriguez-Ruiz; Carolina B Maciel; Emily J Gilmore; Andres Fernandez; Eric S Rosenthal; Jan Claassen; Aatif M Husain; Ji Yeoun Yoo; Elson L So; Peter W Kaplan; Marc R Nuwer; Michel van Putten; Raoul Sutter; Frank W Drislane; Eugen Trinka; Nicolas Gaspard Journal: J Clin Neurophysiol Date: 2021-01-01 Impact factor: 2.590
Authors: Boulenouar Mesraoua; Dirk Deleu; Hassan Al Hail; Faisal Ibrahim; Gayane Melikyan; Hassan Al Hussein; Rajvir Singh; Basim Uthman; Leopold Streletz; Peter W Kaplan; Heinz Gregor Wieser Journal: J Drug Assess Date: 2017-11-10